India, Aug. 20 -- Moderna shares soared as much as 160 per cent on Wednesday after the biotechnology company said its personalised cancer vaccine, developed alongside pharmaceutical giant Merck & Co, had reduced the recurrence of melanoma in a late-stage clinical trial, delivering a record one-day blow to investors who had bet against the stock.

The record surge, which added roughly $30 billion to Moderna's market value according to Reuters, inflicted approximately $5 billion in mark-to-market losses on short sellers, according to data from S3 Partners LLC, bringing their total losses for the year to more than $7 billion.

Moderna Cancer Vaccine: What Did The Trial Find?

The vaccine, known as intismeran autogene and combined with Merck'...